Novavax shares jump after long-awaited FDA approval of its COVID-19 vaccine
By Kamal Choudhury (Reuters) -Novavax shares jumped more than 15% on Monday after the company secured a long-awaited U.S. regulatory approval for its COVID-19 vaccine, albeit with new conditions, which helped allay some investor concerns over the future of the shot. The U.S. Food and Drug Administration approved the vaccine, Nuvaxovid, but limited its use …
Novavax shares jump after long-awaited FDA approval of its COVID-19 vaccine Read More »










